Rosen Law Firm Urges Brainstorm Cell Therapeutics Inc. Investors with Losses to Act Before Deadline

NEW YORK, Nov. 11, 2023 — The legal firm specializing in protecting investor rights, Rosen Law Firm, is issuing a reminder to investors who held securities of Brainstorm Cell Therapeutics Inc. BCLI from August 15, 2022, to September 27, 2023, inclusive. They underscore the impending deadline of January 2, 2024, for the submission of a lead plaintiff in a securities class action lawsuit initiated by the firm.

Entitlement to Compensation

Investors who acquired BCLI shares during the designated Class Period may be entitled to compensation without incurring any out-of-pocket fees or costs, provided they enter into a contingency fee agreement.

Steps to Join the Class Action

To participate in the BCLI class action, investors are instructed to visit the Rosen Law Firm's website or contact Phillip Kim, Esq. directly via email or toll-free call. Those intending to serve as lead plaintiff must move the court by no later than January 2, 2024, and can act independently as a representative party for the rest of the class members.

Selecting Legal Counsel

Investors are advised to select qualified legal representation carefully. It is critical to choose counsel with a proven track record in securities class actions and leadership roles. Rosen Law Firm prides itself on its substantial experience, resources, and recognition by peers within the legal community. Their focus on securities class actions and shareholder derivative litigation has yielded significant settlements and recoveries for investors globally.

About Rosen Law Firm

Rosen Law Firm has consistently ranked prominently for their achievements in securities class actions, with a reputation for procuring substantial investor settlements against numerous high-profile companies. Renowned for their legal acumen, the firm's attorneys are recognized by many reputable sources and have collectively recouped hundreds of millions of dollars for their clients.

Lawsuit Allegations

According to the lawsuit, Brainstorm Cell Therapeutics Inc. allegedly made false and misleading statements or did not fully disclose issues related to the FDA's refusal to file a letter, underestimating the risks associated with the submission of their BLA, leading to investor damages upon revelation of the actual risks.

In conclusion, investors who have incurred losses from their investment in Brainstorm Cell Therapeutics Inc. BCLI during the stated Class Period should move swiftly to secure legal counsel and consider joining the class action before the deadline.

investment, deadline, lawsuit